JP2008518024A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008518024A5 JP2008518024A5 JP2007539091A JP2007539091A JP2008518024A5 JP 2008518024 A5 JP2008518024 A5 JP 2008518024A5 JP 2007539091 A JP2007539091 A JP 2007539091A JP 2007539091 A JP2007539091 A JP 2007539091A JP 2008518024 A5 JP2008518024 A5 JP 2008518024A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- compound according
- alkyl
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 226
- 125000000217 alkyl group Chemical group 0.000 claims 59
- 229910052760 oxygen Inorganic materials 0.000 claims 54
- 229910052757 nitrogen Inorganic materials 0.000 claims 39
- 125000004432 carbon atom Chemical group C* 0.000 claims 30
- 229910052739 hydrogen Inorganic materials 0.000 claims 29
- 239000000203 mixture Substances 0.000 claims 28
- 239000001257 hydrogen Substances 0.000 claims 26
- 229910052717 sulfur Inorganic materials 0.000 claims 19
- 150000002431 hydrogen Chemical class 0.000 claims 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 15
- -1 —NH 2 Chemical class 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 12
- 229920002554 vinyl polymer Polymers 0.000 claims 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 11
- 125000000623 heterocyclic group Chemical group 0.000 claims 11
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 9
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 7
- 125000003107 substituted aryl group Chemical group 0.000 claims 7
- 239000004480 active ingredient Substances 0.000 claims 6
- 125000006239 protecting group Chemical group 0.000 claims 6
- 125000000547 substituted alkyl group Chemical group 0.000 claims 6
- 206010061218 Inflammation Diseases 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000002947 alkylene group Chemical group 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 230000004054 inflammatory process Effects 0.000 claims 5
- 241001465754 Metazoa Species 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 229910052794 bromium Inorganic materials 0.000 claims 3
- 125000002837 carbocyclic group Chemical group 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 229910052740 iodine Inorganic materials 0.000 claims 3
- 125000004437 phosphorous atom Chemical group 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 125000002252 acyl group Chemical group 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 241001481833 Coryphaena hippurus Species 0.000 claims 1
- 125000004442 acylamino group Chemical group 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 150000001540 azides Chemical class 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 claims 1
- 150000003464 sulfur compounds Chemical class 0.000 claims 1
- 125000004001 thioalkyl group Chemical group 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 0 CC1OCC(C(C(*=C)(C(N)=O)N)N)=C1 Chemical compound CC1OCC(C(C(*=C)(C(N)=O)N)N)=C1 0.000 description 5
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62311704P | 2004-10-26 | 2004-10-26 | |
| US62296304P | 2004-10-26 | 2004-10-26 | |
| US62299404P | 2004-10-26 | 2004-10-26 | |
| US62299304P | 2004-10-26 | 2004-10-26 | |
| US62291204P | 2004-10-26 | 2004-10-26 | |
| US62293104P | 2004-10-26 | 2004-10-26 | |
| US62285104P | 2004-10-26 | 2004-10-26 | |
| PCT/US2005/038700 WO2006047661A2 (en) | 2004-10-26 | 2005-10-26 | Phosphonate derivatives of mycophenolic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008518024A JP2008518024A (ja) | 2008-05-29 |
| JP2008518024A5 true JP2008518024A5 (enExample) | 2008-10-16 |
Family
ID=36228469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007539091A Withdrawn JP2008518024A (ja) | 2004-10-26 | 2005-10-26 | ミコフェノール酸のホスホネート誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080171724A1 (enExample) |
| EP (1) | EP1809277A2 (enExample) |
| JP (1) | JP2008518024A (enExample) |
| AU (1) | AU2005299284A1 (enExample) |
| CA (1) | CA2585353A1 (enExample) |
| WO (1) | WO2006047661A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10369133B2 (en) | 2013-07-23 | 2019-08-06 | The University Of Tennessee Research Foundation | Immunosuppressive compounds and therapeutics |
| JP7381190B2 (ja) | 2014-12-26 | 2023-11-15 | エモリー・ユニバーシテイ | Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途 |
| US10450335B2 (en) | 2015-12-15 | 2019-10-22 | Merck Sharp & Dohme Corp. | Antiviral oxime phosphoramide compounds |
| US10736908B2 (en) | 2016-10-26 | 2020-08-11 | Merck Sharp & Dohme Corp. | Antiviral aryl-amide phosphodiamide compounds |
| BR112019012511A2 (pt) | 2016-12-22 | 2019-11-19 | Idenix Pharmaceuticals Llc | compostos antivirais de benzil-amina fosfodiamida, composição farmacêutica e uso do composto |
| KR102626210B1 (ko) | 2017-12-07 | 2024-01-18 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
| EP3823629B1 (en) | 2018-07-19 | 2024-12-25 | Merck Sharp & Dohme LLC | Phosphinic amide prodrugs of tenofovir |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5631370A (en) * | 1988-01-20 | 1997-05-20 | Regents Of The University Of Minnesota | Optically-active isomers of dideoxycarbocyclic nucleosides |
| US5654286A (en) * | 1993-05-12 | 1997-08-05 | Hostetler; Karl Y. | Nucleotides for topical treatment of psoriasis, and methods for using same |
| US5446137B1 (en) * | 1993-12-09 | 1998-10-06 | Behringwerke Ag | Oligonucleotides containing 4'-substituted nucleotides |
| US5493030A (en) * | 1994-02-18 | 1996-02-20 | Syntex (U.S.A.) Inc. | 5-substituted derivatives of mycophenolic acid |
| US5747498A (en) * | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| US5874577A (en) * | 1996-04-03 | 1999-02-23 | Medichem Research, Inc. | Method for the preparing 9-12-(Diethoxyphosphonomethoxy)ethyl!adenine and analogues thereof |
| US6174888B1 (en) * | 1998-05-28 | 2001-01-16 | Novartis Ag | 2-amino-7-(1-substituted-2-hydroxyethyl)-3,5-dihydropyrrolo[3,2-D]pyrimidin-4-ones |
| AU780973B2 (en) * | 1999-06-25 | 2005-04-28 | Vertex Pharmaceuticals Incorporated | Prodrugs of carbamate inhibitors of IMPDH |
| US6767900B2 (en) * | 2000-02-29 | 2004-07-27 | Mitsubishi Pharma Corporation | Phosphonate nucleotide compound |
-
2005
- 2005-10-26 WO PCT/US2005/038700 patent/WO2006047661A2/en not_active Ceased
- 2005-10-26 JP JP2007539091A patent/JP2008518024A/ja not_active Withdrawn
- 2005-10-26 AU AU2005299284A patent/AU2005299284A1/en not_active Abandoned
- 2005-10-26 US US11/666,266 patent/US20080171724A1/en not_active Abandoned
- 2005-10-26 EP EP05822599A patent/EP1809277A2/en not_active Withdrawn
- 2005-10-26 CA CA002585353A patent/CA2585353A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2403258C2 (ru) | Тиазолилдигидроиндазолы | |
| RU2445312C2 (ru) | ПРОИЗВОДНЫЕ 2-МЕТИЛМОРФОЛИН ПИРИДО-, ПИРАЗО- И ПИРИМИДО-ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ mTOR | |
| US8618125B2 (en) | Composition comprising hepatic therapeutic active for treating liver diseases, certain cancers and liver health maintenance | |
| JP2009504763A5 (enExample) | ||
| CZ330896A3 (cs) | Použití látky, která brání nebo minimalizuje oxidaci polynenasycené mastné kyseliny a způsoby s tímto použitím spojené | |
| RU2007124329A (ru) | ПРОИЗВОДНЫЕ 5-ГИДРОКСИБЕНЗОТИАЗОЛА В КАЧЕСТВЕ АГОНИСТОВ β2 АДРЕНОРЕЦЕПТОРОВ | |
| JP2011516511A5 (enExample) | ||
| RU2019116590A (ru) | Трициклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич | |
| CZ2015227A3 (cs) | Trifenylfosfoniové analogy biguanidu, způsob jejich přípravy a jejich použití jako léčiva | |
| JP2008518024A5 (enExample) | ||
| RU2266291C2 (ru) | Халконовые кумарины | |
| RU2003134629A (ru) | Соединения цефема | |
| KR102055176B1 (ko) | 암 치료용 키나제 저해제 | |
| RU2006104024A (ru) | Каппа-агонисты, в особенности для лечения и/или профилактики синдрома раздраженной толстой кишки | |
| WO2013029006A1 (en) | Dengue virus and yellow fever virus therapies | |
| JP2006500372A5 (enExample) | ||
| HRP20120478T1 (hr) | Formulacije koje sadrže spojeve srodne jorumicinu renieramicinu safracinu ili saframicinu i disaharid za liječenje proliferativnih oboljenja | |
| RU2009123645A (ru) | Способы повышения биодоступности ингибитора ренина | |
| WO2021048417A1 (en) | Combination therapies comprising dasatinib for the treatment of cholangiocarcinoma | |
| JP2019518029A5 (enExample) | ||
| KR100268405B1 (ko) | 악성종양 전이억제제 | |
| TWI650141B (zh) | 包含奎寧鹽懸浮液的用於抗癌治療的局部給藥用注射劑組合物 | |
| KR20170106478A (ko) | 수니티닙 프로드러그 및 약학 조성물 | |
| TW200530154A (en) | Compounds having antitumor activity | |
| ES2263835T3 (es) | Terapia combinada contra tumores que comprende derivados de distamicina acriloil sustituidos e inhibidores proteina quinasa (serina/treonina quinasa). |